🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsClinical Trials & ResearchMonthly semaglutide depot formulation — my results so far Page 3

Monthly semaglutide depot formulation — my results so far

tony_orlando Mon, Jul 22, 2024 at 3:23 PM 39 replies 2,686 viewsPage 3 of 8
pete_manc_UK
Senior Member
1,234
5,678
Mar 2024
Manchester, UK
Jul 23, 2024 at 5:42 PM#11
Dr.GutHealth said:
The useful move here is to separate what is established from what is widely repeated.

All true, with one condition: that curve is for people who reached the dose on schedule. Anyone who slowed the ladder for tolerability is on a different, flatter curve, and comparing yourself with the published mean will make you feel like a non-responder when you are not.

17 15TrialNerd_Beth, HPLC_Greg, LibrarianMeg and 14 others
Reply Quote Save Share Report
MASHdoc_SA
Member
456
2,345
Aug 2024
San Antonio, TX
Jul 24, 2024 at 11:02 AM#12
labquiet_amy said:
The dose-response is real but shallow at the top.

Saving this. It is the first explanation that did not require me to already understand it. Adding it to my notes with a link back to this thread.

Last edited: Jul 24, 2024 at 2:02 PM
18 16TrialTracker_MD, JennaRN, LabKate and 15 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Jul 25, 2024 at 4:21 AM#13
Dr.GutHealth said:
The useful move here is to separate what is established from what is widely repeated.

Pushing back on Dr.GutHealth here. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.

19 17JessicaH_TX, KevinCompounds, TirzTom and 16 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
raj_cambridge
Member
489
2,123
Jun 2024
Cambridge, MA
Jul 25, 2024 at 9:40 PM#14

One concrete data point for the thread. If you are going to change something, change one thing and give it long enough to express itself. Four weeks is the usual minimum for anything pharmacological on this board, and two weeks of data has told you almost nothing.

That is the short version; the long version is somebody else's post.

Last edited: Jul 25, 2024 at 10:40 PM
20 18PharmHunterJen, TomTeleRx, DoseLogDan and 17 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Jul 26, 2024 at 2:58 PM#15

Moderator note: a couple of off-topic posts removed. Thread quality here is what the rules are for. Keep it up.

21 19PurityPaulOR, MaxMetOK, MounjBrad and 18 others
Reply Quote Save Share Report

Similar Threads

FLOW trial: semaglutide renal outcomes — NEJM publication review14 replies
SELECT trial: semaglutide 2.4mg cardiovascular outcomes — 4yr data9 replies
TRIUMPH program (retatrutide) — Phase 3 trial design and endpoints13 replies
Orforglipron ATTAIN trials — oral non-peptide GLP-1 agonist8 replies
CagriSema (amylin + semaglutide) — REDEFINE Phase 3 results20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register